Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
NOVEL PROCESS FOR PREPARATION OF GLUCOCORTICOID STEROIDS
Document Type and Number:
WIPO Patent Application WO/2016/120891
Kind Code:
A1
Abstract:
The present invention discloses a process for the preparation of 16, 17-acetals of pregnane derivatives having formula (I) wherein each substituent is independently selected from; R1 is H or CH3; R2 is C1-C6 linear or branched alkyl, alkynyl group or cycloalkyl group; aryl or heteroaryl group; or R1 and R2 combine to form saturated, unsaturated C3-C6 cyclic or heterocyclic ring; R3 and R4 are same or different and each independently represents H or halogen; R5 is -OH or –OCOR wherein R represents H or C1-C6 linear, branched or cyclic alkyl group that may be substituted.

Inventors:
TRIPATHI, Vinayak (1001, Akash Deep Building 26-A,Barakhamba Road, New Delhi 1, 110001,, IN)
KUMAR, Rajesh (1001, Akash Deep Building 26-A,Barakhamba Road, New Delhi 1, 110001,, IN)
BHUWANIA, Rohit (1001, Akash Deep Building 26-A,Barakhamba Road, New Delhi 1, 110001,, IN)
BHUWANIA, Binay Kumar (1001, Akash Deep Building 26-A,Barakhamba Road, New Delhi 1, 110001,, IN)
Application Number:
IN2016/050031
Publication Date:
August 04, 2016
Filing Date:
January 29, 2016
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
CORAL DRUGS PVT. LTD. (1001, Akash Deep Building 26-A,Barakhamba Road, New Delhi 1, 110001,, IN)
International Classes:
A61K31/58; C07J5/00
Domestic Patent References:
WO2002038584A12002-05-16
Foreign References:
US4695625A1987-09-22
EP0262108A11988-03-30
Attorney, Agent or Firm:
ARVIND, Chitra (Rajeshwari & Associates, Amsoft Business CentreUnitech Trade Centre,Sector 43, Haryana, Gurgaon 2, 122 002,, IN)
Download PDF:
Claims:
WE CLAIM:

1. A process for the preparation of 16, 17-acetals of pregnane derivatives having formula (I)

R4

Formula I

wherein each substituent is independently selected from;

Ri is H or CH3;

R2 is Ci-C6 linear or branched alkyl, alkynyl group or cycloalkyl group; aryl or heteroaryl group; or

Ri and R2 combine to form a saturated, unsaturated C3-C6 cyclic or heterocyclic ring; R3 and R4 are same or different and each independently represents H or halogen; R5 is -OH or -OCOR wherein R represents H or Ci-C6 linear, branched or cyclic alkyl group that is substituted;

comprising the steps of:

i. dihydroxylation of the compound of formula II 2-((105,135, 145)-10,13-dimethyl-3- oxo-6,7,8,10, 12,13, 14, 15-octahydro-3H-cyclopenta[(3]phenanthren- 17-yl)-2-oxoethyl acetate to obtain the compound of formula III;

Formula II Formula III

ii. bromination of the compound of formula III to obtain the hydroxylated brominated compound of formula IV;

Formula IV

iii. debromination of the compound of formula IV to obtain the compound of formula V;

iv. deacetylation of the compound of formula V to obtain the compound of formula VI;

Formula VI

alkylation of the compound of formula VI to obtain the compound of formula I.

A process for the preparation of 16, 17-acetals of pregnane derivatives having formula

(VII) as claimed in clai

wherein Ri and R2 is H;

R5 is OH;

R3 and R4 independently represents H or halogen;

3. The process as claimed in step (i) of claim 1 , wherein dihydroxylation of compound of formula (II) is carried out with an oxidizing agent, selected from group comprising potassium permanganate, potassium dichromate, chromic acid, peroxyacids or mixtures thereof, preferably, potassium permanganate, formic acid and sodium metabisulphite to form compound of formula (III).

4. The process as claimed in step (ii) of claim 1, wherein compound of formula (III) is brominated with a brominating agent, selected from the group comprising dibromantin, N-bromosuccinamide, preferably, dibromatin to form compound of formula (IV) in presence of organic solvent, selected from the group comprising tetrahydrofuran, acetone, N,N- dimethyl formamide, DMSO, methanol, methylene dichloride, acetonitrile, ethyl acetate, diethyl ether, 1-butanol, methylethyl ketone, 1- propanol, formamide, preferably, tetrahydrofuran.

5. The process as claimed in step (iii) of claim 1, wherein compound of formula (IV) is debrominated to form compound of formula (V) in presence of catalyst, Rt— SH (VIII) with an aprotic solvent at appropriate temperature, wherein

Rt— SH

Formula VIII

wherein Rt is -CH2COOH or -CH2CH2COOH preferably Rt is -CH2COOH.

6. The process as claimed in claim 5, wherein catalyst is selected from the group comprising chromous or chromium sulfate, chromous or chromium chloride or its hydrate, preferably, chromium chloride hexahydrate.

7. The process as claimed in claim 5, wherein aprotic solvent is selected from the group comprising DMF, DMAC, acetone, methylene chloride, THF, acetonitrile, DMSO and mixtures thereof, preferably, DMF and DMSO.

8. The process as claimed in step (iv) of claim 1, wherein compound of formula (V) is deacylated to form compound of formula (VI) 16 -Hydroxy Prednisolone (16-HPN), wherein C-16 and C-17 is OH.

9. The compound of formula (VI) as claimed in claim 8, wherein the starting material is compound of formula (II).

10. The process as claimed in step (v) wherein compound of formula (VI) is converted to compound of formula (I) by deacetylation and alkylation with reagents selected from group comprising N-butyraldehyde, cyclohexane carboxaldehyde, sodium metabisulphite complex, isobutyryl chloride, acetone, hydrofluoric acid, isopropenyl acetate, dibromantin, select fluor, perchloric acid, 3,3-dimethyl butyryl chloride and triethylamine or combination thereof.

11. The compound of formula (I) as claimed in claim 1, wherein Ri is -H, R2 is - CH2CH2CH3, R5 is -OH, and wherein compound of formula (VI) is converted to compound of formula (I) by treating with N-butyraldehyde and hydrochloric acid.

12. The compound as claimed in claim 11, wherein desired epimer A is in range of 54 to 44 % at temperature between -5° to - 15 °C during addition of N-butyraldehyde and -0° to - 10 °C till completion of reaction.

13. The compound of formula (I) as claimed in claim 1, wherein Ri is -H, R2 is -CeHn, R5 is -OCOCH(CH3)2, and wherein compound of formula (VI) is converted to compound of formula (I) by treating with cyclohexane carboxaldehyde, sodium metabisulphite and isobutyryl chloride.

14. The compound of formula (I) as claimed in claim 1, wherein Ri is -CH3, R2 is -CH3, R5 is -OH, and wherein compound of formula (V) wherein R3 and R4 is H is converted to compound of formula (I) by treating with acetone and perchloric acid.

15. The compound of formula (I) as claimed in claim 1, wherein Ri is -CH3, R2 is -CH3, R5 is -OH, R3 is -F, R4 is -H, and wherein compound of formula (II) wherein R4 is H is converted to compound of formula (I) by treating with acetone, dibromantin, hydrofluoric acid.

16. The compound of formula (I) as claimed in claim 1, wherein Ri is -CH3, R2 is -CH3, R5 is -OH, R3 is -H, R4 is -F, and wherein compound of formula (V) wherein R3 and R4 is H is converted to compound of formula (I) by treating with acetone, isopropenyl acetate and select fluor.

17. The compound of formula (I) as claimed in claim 1, wherein Ri and R2 is -CH3, R5 is -OH, R3 is -F, R4 is -H, and wherein compound of formula (II) wherein R4 is H is converted to compound of formula (I) by treating with perchloric acid, dibromantin, hydrofluoric acid and 3, 3 -dimethyl butyryl chloride.

18. The compound of formula (VII) as claimed in claim 2, wherein Ri and R2 is H, R5 is - OH, R3 is -F, R4 is -H, and wherein compound of formula (II) wherein R4 is H is converted to compound of formula (VII) by treating with perchloric acid and hydrofluoric acid.

Description:
NOVEL PROCESS FOR PREPARATION OF GLUCOCORTICOID STEROIDS Field of the Invention

The present invention provides a synthetic process for the preparation of 16, 17-acetals of pregnane derivatives.

Background of the Invention

Glucocorticoids have a number of diverse effects in different body tissues. Glucocorticoids, in topical, oral and inhaled formulations, are useful for their anti-inflammatory and immunosuppressive properties. Several glucocorticoids such as budesonide and ciclesonide are used for treatment of several disorders.

The synthesis and purification of glucocorticoids have been disclosed at different instances. However, most of these synthetic procedures involve toxic solvents or long reaction times and are ineffective for large scale synthesis. For instance, US 3,92,9768 discloses a process for preparation of budesonide by reacting 16, 17-dihydroxy compound with aldehyde in solvents such as dioxane, methylene chloride or their combinations.

DE 4129535 discloses a process for the synthesis of Ciclesonide which involves the intermediate 16A, 17-[(7?,S)-cyclohexylmethylenedioxy]-l 13, 21-dihydroxy-pregna-l 4- dien-3,20-one which is obtained by an acid catalysed reaction of 11 , 16 , 17, 21-tetra hydroxypregna-l,4-dien-3,20-one with cyclohexane aldehyde.

WO 02/38584 discloses the synthesis of Ciclesonide by reacting corresponding 16, 17-ketals with a cyclohexane aldehyde in the presence of 70% perchloric acid, 1-nitropropane as solvent. However, perchloric acid is a dangerous solvent and can cause serious accidents with fatal consequences.

US Patent No. 6169178 relates to a process for the preparation of budesonide and of 16, 17- acetals of pregnane derivatives structurally co-related thereto comprising treating 16, 17-dios or of 16, 17-ketals or cyclic acetals with aldehydes in the presence of aqueous hydrobromic acid or hydroiodic acid used as reaction catalyst or solvents. However, hydroiodic and other hydrohalic solvents are corrosive, light sensitive and expensive. Further, these acids also post environmental problems. Notwithstanding the use of hydrohalo acids requires use of special equipment since they are extremely corrosive and consequently increase the cost of production.

US 5,55,6964 discloses a process for the preparation of budesonide by reacting 16 - Hydroxy Prednisolone in acetonitrile in the presence of /^-toluene sulfonic acid as a catalyst. There are certain other patents that use alkyl sulfonic acid instead of aryl sulfonic acid for the synthesis of budesonide or similar compounds. However, sulfonic acids are hazardous solvents and FDA has expressed significant concern over the presence or traces of sulfonic acid in pharmaceutical products. Hence, there is a need to have a process for the synthesis 16, 17- acetals of pregnane compounds that is industrially scalable and which does not involve the use of harmful solvents.

Object of the Invention

An object of the present invention is to provide an industrially scalable, viable process for the synthesis of 16, 17-acetals of pregnane compounds without the use of toxic and harmful solvents.

Brief Description of the Invention

The present invention discloses a process for the preparation of 16, 17-acetals of pregnane derivatives having formula I

R 4

Formula I wherein each substituent is independently selected from;

Ri is H or CH 3 ;

R 2 is Ci-C 6 linear or branched alkyl, alkynyl group or cycloalkyl group; aryl or heteroaryl group; or

Ri and R 2 combine to form C 3 -C 6 saturated, unsaturated cyclic or heterocyclic ring;

R 3 and R4 are same or different and each independently represents H or halogen;

R5 is -OH or -OCOR wherein R represents H or Ci-C 6 linear, branched or cyclic alkyl group that may be substituted.

The present invention discloses, a novel process for preparing the compounds of formula I; i. Dihydroxylation of the compound of formula II being 2-((105, 135, 145)-10, 13- dimethyl-3-oxo-6,7,8, 10, 12,13, 14,15-octahydro-3H-cyclopenta[(3]phenanthren-17-yl)- 2-oxoethyl acetate (3TR) to obtain the compound of formula III

ii. Bromination of the compound of formula III to obtain the hydroxylated brominated compound of formula IV

iii. Debromination of the compound of formula IV to obtain the compound of formula V iv. Deacetylation of the compound of formula V to obtain the compound of formula VI v. Alkylation of 16, 17-diol of the compound of formula VI to obtain the compound of formula I.

Detailed Description of the Invention

The present invention discloses a process for the preparation of 16, 17-acetals of pregnane derivatives having formula I

Formula I

wherein each substituent is independently selected from;

Ri is H or CH 3 ;

R 2 is CrC 6 linear or branched alkyl, alkynyl group or cycloalkyl group; aryl or heteroaryl group; or

Ri and R 2 combine to form C 3 -C 6 saturated, unsaturated cyclic or heterocyclic ring;

R 3 and R4 are same or different and each independently represents H or halogen;

R5 is -OH or -OCOR wherein R represents H or Ci-C 6 linear, branched or cyclic alkyl group that may be substituted, comprising the steps of:

i. dihydroxylation of the compound of formula II 2-((105,135, 145)-10,13-dimethyl-3- oxo-6,7,8,10, 12,13, 14, 15-octahydro-3H-cyclopenta[(3]phenanthren- 17-yl)-2-oxoethyl acetate to obtain the compound of formula III;

Formula IV 111. debromination of the compound of formula IV to obtain the compound of formula V;

Formula V

IV. deacetylation of the compound of formula V to obtain the compound of formula VI;

Formula VI

v. alkylation of the compound of formula VI to obtain the compound of formula I.

In an embodiment the present invention discloses a process for the preparation of 16, 17- acetals of pregnane derivatives having formula (VII)

Formula (VII)

wherein Ri and R 2 is H;

R 5 is OH;

R 3 and R4 independently represent H or halogen;

The compounds of formula I and formula VII may include but are not limited to the following compounds as presented at table 1 : Table 1; Exemplary compounds of present invention

The compounds of the present invention may be prepared by a process as described herein below:

FbrmJa-l FbrmJa-VI Fbrrrula-V

Scheme 1: Process of the present invention

The process of the present invention comprises of the following steps:

i. Dihydroxylation of the compound of formula II being 2-((105, 135, 145)-10, 13- dimethyl-3-oxo-6,7,8, 10, 12,13, 14,15-octahydro-3H-cyclopenta[(3]phenanthren-17-yl)- 2-oxoethyl acetate (3TR) to obtain the compound of formula III

ii. Bromination of the compound of formula III to obtain the hydroxylated brominated compound of formula IV

iii. Debromination of the compound of formula IV to obtain the compound of formula V iv. Deacetylation of the compound of formula V to obtain the compound of formula VI v. Alkylation of 16, 17-diol of the compound of formula VI to obtain the compound of formula I.

The process of the present invention may be suitably started from the compound of formula II, known by its IUPAC name 2-((105,135, 145)-10,13-dimethyl-3-oxo-6,7,8, 10,12, 13, 14, 15- octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate and hereinafter referred to as 3TR (formula II). 3TR is suitably dihydroxylated by an oxidizing agent. The oxidizing agent may be selected from the group comprising potassium permanganate, potassium dichromate, chromic acid, peroxyacids or mixtures thereof, preferably potassium permanganate, formic acid and sodium metabisulphite to form compound of formula (III). Under acidic conditions formic acid promotes oxidation reaction and sodium metabisulfite quench the oxidized reaction product to protect the formation of further oxidative impurities in the formulated product. The dihydroxylation of 3TR results in a compound of formula III.

In the present invention, dihydroxylation of compound of formula (II) is carried out with an oxidizing agent, selected from group comprising potassium permanganate, potassium dichromate, chromic acid, peroxyacids or mixtures thereof, preferably potassium permanganate, formic acid and sodium metabisulphite to form compound of formula (III).

The process of the present invention involves the bromination of the compound of formula III to yield the hydroxylated brominated compound of formula IV. The bromination of compound of Formula III may be conducted by suitably reacting the compound of Formula III with a brominating agent selected from the group comprising dibromantin, N- bromosuccinamide etc, preferably dibromantin, in the presence of a solvent. The solvent may be selected from the group comprising tetrahydrofuran, acetone, N, N- dimethyl formamide, DMSO, methanol, methylene dichloride, acetonitrile, ethyl acetate, diethyl ether, 1 -butanol, methylethyl ketone, 1-propanol, formamide and the like, preferably tetrahydrofuran.

In the present invention, compound of formula (III) is brominated with a brominating agent, selected from the group comprising dibromantin, N-bromosuccinamide preferably dibromatin to form compound of formula (IV) in presence of organic solvent, selected from the group comprising tetrahydrofuran, acetone, N,N- dimethyl formamide, DMSO, methanol, methylene dichloride, acetonitrile, ethyl acetate, diethyl ether, 1-butanol, methylethyl ketone, 1-propanol, formamide, preferably tetrahydrofuran.

The debromination of compound of formula IV may be conducted in presence of a catalyst, a thiol compound and an aprotic solvent to obtain the compound of formula V.

In the present invention, catalyst is selected from the group comprising chromous or chromium sulfate, chromous or chromium chloride or its hydrate, preferably chromium chloride hexahydrate. The chromium (III) can be recycled to chromium (II) as is known to those skilled in the art. The means for recycling chromium (III) to chromium (II) includes zinc, magnesium, zinc amalgam and magnesium amalgam. Preferred is zinc and magnesium; most preferred is zinc. It is preferred that when the means for recycling is zinc it be present as zinc dust.

Thiols include compounds of the formula R t -SH (Formula VIII). It is preferred that R t be— CH 2 -COOH or -CH 2 CH 2 -COOH; it is more preferred that the thiol be thioglycolic (thiovanic) acid where R t is— CH 2 —COOH. Improved chemical yields result from the use of greater than 1 equivalent of the thiol, preferably from about 1.5 to about 3.0 equivalents. In the present invention compound of formula (IV) is debrominated to form compound of formula (V) in presence of catalyst, Rt— SH (VIII) with an aprotic solvent at appropriate temperature, wherein

R t — SH

Formula VIII

wherein R t is -CH 2 COOH or -CH 2 CH 2 COOH preferably R t is -CH 2 COOH.

Suitable aprotic solvents include DMF, DMAC, acetone, methylene chloride, THF, acetonitrile, DMSO and mixtures thereof. Alcoholic solvents include methanol, ethanol, isopropanol and butanol. Preferred are DMF and DMSO. The temperature is not critical; that temperatures between about -50°C to about 100°C are operable and preferred is about room temperature (20°C-25°C) or up to about 50°C. Better results can be obtained if the temperature is maintained between -10° and 30°C.

In the present invention, aprotic solvent is selected from the group comprising DMF, DMAC, acetone, methylene chloride, THF, acetonitrile, DMSO and mixtures thereof, preferably DMF and DMSO.

In one embodiment, the compound of formula V may be optionally purified and utilized for commercial purposes. When on C-16 and C-17 of the compound of formula V is "OH", then the compound hydrolyses from 2-oxo-2-((8S,9S,10R,l 15, 135,145, 16 ?,175)-11, 16,17- trihydroxy- 10, 13-dimethyl-3-oxo-6,7,8,9, 10,l l, 12, 13, 14, 15,16, 17-dodecahydro-3H-cyclo penta[a]phenanthren- 17-yl)ethyl acetate to 16 - Hydroxy Prednisolone (Formula VI), also known as 16-HPN.

The compound of formula V may be converted to compound of formula VI, C- 16 and C- 17 of the compound of formula V is "OH", then the compound hydrolyses from 2-oxo-2- ((8S,9S, 10R, l lS, 13S,14S,16R,17S)-l l, 16,17-trihydroxy- 10, 13-dimethyl-3-oxo-6,7,8,9,10, l l,12, 13,14, 15,16, 17-dodecahydro-3H-cyclopenta[(3]phenanthren- 17-yl)ethyl acetate to 16 - Hydroxy Prednisolone(Formula VI), also known as 16-HPN.

In the present invention, compound of formula (V) is deacylated to form compound of formula (VI) 16 -Hydroxy Prednisolone (16-HPN), wherein C- 16 and C- 17 is OH.

In the present invention, the starting material for the preparation of compound of formula (VI) is compound of formula (II).

In another embodiment, the compound of formula V may be further processed to obtain the compound of formula I. The compound of formula V may be converted to the compound of formula I by the sequential steps of deacetylation and alkylation The same are illustrated at scheme 1 (conversion of formula V to VI and subsequent conversion of formula VI to formula I). The compound of formula VI may be converted to the compound of formula I by deacetylation and alkylation. The compound of formula VI may be converted to the compound of formula I by reacting with reagents selected from group comprising N- butyraldehyde, cyclohexane carboxaldehyde, sodium metabisulphite complex, isobutyryl chloride, acetone, hydrofluoric acid, isopropenyl acetate, dibromantin, select fluor, perchloric acid, 3,3-dimethyl butyryl chloride and triethylamine or combination, preferably N- butyraldehyde and hydrochloric acid i.e. Budesonide. The epimer A ratio is in range of 54 to 44 % at temperature between -5° to - 15 °C during addition of N-butyraldehyde and -0° to -10 °C till completion of reaction.

In an embodiment of the present invention the compound of formula (VI) is converted to compound of formula (I) comprising Ri is -H, R 2 is -CH 2 CH 2 CH 3 , R5 is -OH, by treating with N-butyraldehyde and hydrochloric acid.

In the present invention, the compound of formula (I) comprising Ri is -H, R 2 is - CH 2 CH 2 CH 3 , R5 is -OH, has desired epimer A ratio in range of 54 to 44 % at temperature between -5° to - 15 °C during addition of N-butyraldehyde and -0° to -10 °C till completion of reaction.

The compound of formula VI may be converted to the compound of formula I by deacetylation and alkylation. The compound of formula VI may be converted to the compound of formula I by reacting with the reagent selected from the group comprising N- butyraldehyde, cyclohexane carboxaldehyde, sodium metabisulphite complex, isobutyryl chloride, acetone, hydrofluoric acid, isopropenyl acetate, dibromantin, select fluor, perchloric acid, 3,3-dimethyl butyryl chloride and triethylamine or combination, preferably cyclohexane carboxaldehyde is used to form compound of formula I i.e. Ciclesonide.

In an embodiment of the present invention the compound of formula (VI) is converted to compound of formula (I) comprising Ri is -H, R 2 is -C 6 Hii, R5 is -OCOCH(CH 3 ) 2 , and) is converted to compound of formula (I) by treating with cyclohexane carboxaldehyde, sodium metabisulphite and isobutyryl chloride.

The compound of formula V may be converted to the compound of formula I by reacting with the reagent selected from the group comprising N-butyraldehyde, cyclohexane carboxaldehyde, sodium metabisulphite complex, isobutyryl chloride, acetone, hydrofluoric acid, isopropenyl acetate, dibromantin, select fluor, perchloric acid, 3,3-dimethyl butyryl chloride and triethylamine or combination, preferably acetone and perchloric acid i.e. Desonide.

In an embodiment of the present invention the compound of formula (V) comprising R 3 and R4 is H is converted to compound of formula (I) comprising Ri is -CH 3 , R 2 is -CH 3 , R5 is - OH, by treating with acetone and perchloric acid. The compound of formula II may be converted to the compound of formula I by reacting with the reagent selected from the group comprising N-butyraldehyde, cyclohexane carboxaldehyde, sodium metabisulphite complex, isobutyryl chloride, acetone, hydrofluoric acid, isopropenyl acetate, dibromantin, select fluor, perchloric acid, 3,3 -dimethyl butyryl chloride and triethylamine or combination, preferably acetone, dibromantin, hydrofluoric acid i.e. Triamcinolone acetonide.

In an embodiment of the present invention the compound of formula (II) comprising R4 is H converted to compound of formula (I) comprising Ri is -CH 3 , R 2 is -CH 3 , R5 is -OH, R 3 is - F, R 4 is -H, by treating with acetone, dibromantin, hydrofluoric acid.

The compound of formula V may be converted to the compound of formula I by reacting with the reagent selected from the group comprising N-butyraldehyde, cyclohexane carboxaldehyde, sodium metabisulphite complex, isobutyryl chloride, acetone, hydrofluoric acid, isopropenyl acetate, dibromantin, select fluor, perchloric acid, 3,3 -dimethyl butyryl chloride and triethylamine or combination, preferably acetone, isopropenyl acetate and select fluor i.e. Flusinolide

In an embodiment of the present invention the compound of formula (V) comprising R 3 and R4 is H is converted to compound of formula (I) comprising Ri is -CH 3 , R 2 is -CH 3 , R5 is - OH, R 3 is -H, R4 is -F, by treating with acetone, isopropenyl acetate and select fluor.

The compound of formula II may be converted to the compound of formula I by reacting with the reagent selected from the group comprising N-butyraldehyde, cyclohexane carboxaldehyde, sodium metabisulphite complex, isobutyryl chloride, acetone, hydrofluoric acid, isopropenyl acetate, dibromantin, select fluor, perchloric acid, 3,3 -dimethyl butyryl chloride and triethylamine or combination, preferably perchloric acid, dibromantin, hydrofluoric acid and 3, 3 -dimethyl butyryl chloride i.e. Triamcinolone acetonide.

In an embodiment of the present invention the compound of formula (II) comprising R 4 is H is converted to compound of formula (I) comprising Ri and R 2 is -CH 3 , R5 is -OH, R 3 is -F, R4 is -H, by treating with acetone, isopropenyl acetate and select fluor.

The compound of formula II may be converted to the compound of formula VII by reacting with the reagent selected from the group comprising N-butyraldehyde, cyclohexane carboxaldehyde, sodium metabisulphite complex, isobutyryl chloride, acetone, hydrofluoric acid, isopropenyl acetate, dibromantin, select fluor, perchloric acid, 3,3 -dimethyl butyryl chloride and triethylamine or combination, preferably treating with perchloric acid and hydrofluoric acid i.e Triamcinolone.

In an embodiment of the present invention the compound of formula (II) comprising R 4 is H is converted to compound of formula (VII) comprising Ri and R 2 is H, R5 is -OH, R 3 is -F, R4 is -H, by treating with perchloric acid and hydrofluoric acid. The compound of formula I may be optionally purified to obtain a pure compound. Such purification may be done by means of crystallization or column chromatography.

Advantages of the present invention:

1. The process of the present invention uses commonly available and inexpensive materials.

2. The process is simple and does not involve any toxic materials.

3. The process yields several intermediates that have biological activity and commercial utility.

The invention will now be further illustrated by non limiting examples.

Working Examples:

Example- 1: Process for preparation of 16-HPN from 3TR

Stage-I

Stage- 1 Stage-I I

Stage-IV

1 6-HPN acetate 1 6-HPN

Scheme 2: Synthesis of 16HPN from 3TR

Stage-I (oxidation)

Charge 750L of acetone (50 volume), 39L of purified water (2.60 volume) and 15 Kg of 3TR (40.93mol) in a SS Reactor at ambient temperature. Cool to -7°C to -5°C than added 6.0L of formic acid (159.03 mol) and 9.0 kg of potassium permanganate (56.95 mol). Maintain at - 5°Cto -3°C for 30 minutes. In-process check by TLC, 3TR should be less than 1.0%. Added 1.5kg sodium metabisulphite (7.89 mol solution in 12L of purified water at -5°C to -3°C then added 3.0 kg of hyflow super cell at 15°C (+2°C) and filter through 10.0 kg of hyflowbed at 27°C(+3°C) and wash with 150L of acetone Added 1.5 kg of activated charcoal, Stir and filter through hyflow bed and wash with 60L of acetone. Total filtrate was distilled under reduced pressure, while maintaining temperature below 45°C. Added 81L of purified water and cool to 5°C+5°C. Filter through centrifuge and wash with 156L of purified water. Wet material is dry at 60°+5°C till moisture less than 0.50%, Yield=15 kg, HPLC purity=98%.

Stage-II (Bromination)

Charge 75L of tetrahydrofuran, 16L of purified water and 15.0 kg of Stage-I (37.46 mol) in a glass reactor. Cool to -6°C (+2°C) and added 7.50 kg of dibromantin (26.23 mol) and 0.60L of perchloric acid (9.38 mol) and maintain at -6°C (+2°C) for one hour. In-process check by TLC, stage-I should be less than 0.50%. Reaction mass is quench in 390L of purified water at ~5°C. Raised the temperature to 25°C and maintained for 01 hour, filter through centrifuge and wash with 828L of purified water or till neutral pH. Wet material is dry at 40°C+5°C till moisture content should be less than 10%, Yield=21.0kg, HPLC purity=97%.

Stage-Ill (Debromination)

Charge 68.0L of N, N-dimethyl formamide(3.238volume) and 21.0kg of stage-II (42.22 mol) in glass reactor, start argon gas purging and cool to -5°C. Charge 13.0L of N,N- dimethylformamide (0.619volume) , 9.70L of dimethylsulfoxide(0.462volume), 1.62kg of chromium chloride hexahydrate (6.51 mol) and 1.94 kg of zinc dust (0.703 mol). Cool to - 10°Cand added 5.50L of thioglycolic acid (79.21 mol). Maintain for one hour while maintaining temperature around -10°C. In-process check by TLC, stage-II should be less than 1.0%. Added 310 L of purified water and cool to 0°C. Filter through centrifuge and wash with 1600L of purified water. Wet material is dry at 60°C+ (5°C) till moisture content less than 6.0%, Yield=15.0kg, HPLC Purity=90%.

Charge 150L of methylene chloride (10 volume), 150L of methanol (10 volume.) and 15.0kg (30.16 mol) of stage-Ill in a SS Reactor. Heat to clear solution then added 3.0 kg of activated charcoal (20%) and reflux for 04 hours, Filter through hyflow bed and wash with 75L of methylene chloride (5 volume), and 75L of methanol (5 volume) mixture. Total filtrate is distilled till last drop and added 75L (5 volume) of methylene dichloride, reflux for 04 hours than cool to 40°C+(5°C), Filter through centrifuge and wash with 15L (one volume) of methylene chloride. Wet material is dry at 60°C (+5°C) till moisture contents less than 1.0% (Yield =13.0kg, HPLC Purity=96%). Further charge 65.0L (5volume) of ethyl acetate and 13.0 kg (1.0 mol) of purified material. Heat to reflux and maintain for 04 hours under reflux, then cool to 40°C. Filter through centrifuge and wash with 13.0L (one volume) of ethyl acetate. Wet material is dry at 60°C (+5°C) till moisture contents less than 0.50%, Yield=12.0kg, HPLC Purity=98.6%.

Stage-IV (Deacetylation)

Charge 5.83L of methanol (10 volume) and 5.83L of methylene chloride (10 volume) in a glass flask and added 583 gm of 16-HPN acetate(1.397mol) at RT. Start argon gas purging and cool to 0°C to 5°C under argon purging. Prepare 11.66 gm of sodium hydroxide (0.2915mol) solution in 0.583L of methanol (one volume) under argon purging and cool to 0°Cto 5°C. Sodium hydroxide solution is charge in reaction mass at 0°C to 5°C. Maintained the reaction mass at 0°C to 5°C for one hour, In-process check by TLC against 16-HPN acetate it should be nil. Adjust pH to neutral by 21.40ml of acetic acid (0.3742 mol); distill under reduced pressure while maintaining temperature below 40°C, till dry. Cool to ambient temperature and added 1.166L of purified water (02 volume). Cool to 0°C and maintain for one hour. Filter and wash with 300ml of purified water. Dry at 60°C (+5°C) till moisture content less than 1.0%, Yield=490gm (93.50%), HPLC Purity=98.97%, Single impurity= 0.40%. Example 2: Process of synthesis of Budesonide from 16-HPN

16-HPN Budesonide

Charge 800 ml of aqueous hydrochloric acid (8 volume) in a glass flask, start nitrogen gas purging and Cool to -5°C and maintain for 15 min. then added 100 gm of stage-I (0.27 mol) at -5°C and stir for 15 min., added 30 ml of N-butyraldehyde (0.33 mol) while maintaining temperature -5°C to 0°C in around 30 minutes and maintain at 0°C to 5°C for 150 min. under stirring. In-process check by TLC against stage-I, it should be nil. Reaction mass is quench in 1200 ml of purified water (12 volume) at 5°C to 10°C and stir for 15 min. Added solution of 100 kg of sodium bicarbonate (1.19 mol) and 1 ml of purified water (10 volume) in reaction mass at 5°C to 10°C. Stir at 5°C to 10°C for 15 min. Filter and wash with purified water till neutral pH. Wet material is dry at 50°C (+5°C) till moisture contents less than 1.0 %, Yield =110 gm (96.49%), HPLC purity=96.45%, single impurity=1.29%, Epimer-A=47.76%, Epimer-B=49.69%.

(Purification)

Charge 2.5 L of methanol (25 volume) in a Glass flask and added 100 gm of above mentioned crude product. Dissolved at 25°C+5°C till clear solution, added 10 gm of activated charcoal and stir for 30 min. than filter through hyflow bed and wash with 200 ml of methanol (2 volume). Combined filtrates charged in a Glass flask and cool to 10°C to 15°C and added 5.40 L of purified water (54 volume) at 5°Cto 10°C, stir for 15min., filter and wash with purified water. Wet material is dry at 50°C (+5°C) under vacuum till moisture content less than 0.50%, Output=90.0gm, HPLC purity=99.66%, single impurity=0.1%, Epimer-A=44.47%, Epimer-B=55.01%.

Example 2.1: Scale-up process of manufacturing of Budesonide from 16-HPN

Charge 40 L of aqueous hydrochloric acid (8 volume) in a glass flask, start nitrogen gas purging and Cool to - 10°C and maintain for 15 min. then added 5.0 kg of stage-I (13.315 mol) at - 10°C and stir for 45 min. added 1.5 L of N-butyraldehyde (16.68 mol) while maintaining temperature -7°C to - 11°C in around 30 minutes and maintain at -2°C to -6°C for 60 min. under stirring In-process check by TLC against stage-I, it should be nil. Reaction mass is quench in 60 L of purified water (12 volume) at 5°C to 10°C and stir for 15 min. Added solution of 5.0 kg of sodium bicarbonate (59.525 mol) and 50L of purified water (10 volume) in reaction mass at 5°Cto 10°C. Stir at 5°C to 10°C for 15 min. Filter and wash with purified water till neutral pH. Wet material is dry at 50°C (+5°C) till moisture contents less than 1.0 %, Yield =5.293 kg (94.46%), HPLC purity=95.45%, single impurity=1.45%, Epimer-A=53.51 %, Epimer-B=43.78% Effect of temperature and its variation on epimer ratio (A and B) with respect to batch size (From lab to commercial batch)

The results are shown in Table 1:

Table 1:

Comparative data of budesonide Lab development and Plant batches

Reaction Results temperat Tempera (Isomer ratio) ure ture/time Remarks

Exp.

during after Time

NoJB Inpu Out Addition

addition addition durati

atch t put time

of till on

No.

N- completi

butyrald on Epimer Epime ehyde -A r-B

0°Cto

(-)5°C to

0.10k 0.11 -30 min 5°C/ 150 150Mi 46.76

0°C

14020 g kg min n. 49.69% %

0°C to

(-)5°C to

0.10k 0.11 -30 min 5°C/ 150 150Mi 51.09

0°C

14021 g kg min n. 44.34% %

0°C to

(-)5°C to

2.00k 2.22 -30 min 5°C/ 150 150Mi 62.51

0°C

14022 g kg min n. 35.29% %

(-) 2°C

(-)7°C to to (-)

-30 min

2.00k 2.22 (-) 11°C 6°C/60 60Min 45.94

14023 g kg min 50.54% %

(-) 2°C

(-)7°C to to (-)

-30 min

3612- 5.0 5.29 (-) 11°C 6°C/ 60 60Min 43.78

14005 Kg 3kg min 53.51% %

(-) 2°C

(-)7°C to to (-)

-30 min

3612- 5.0 5.27 (-) 11°C 6°C/60 60Min 43.42

14006 Kg 3kg min 53.34% % (-) 2°C

(-)7°C to to (-)

-30 min

3612- 5.0 5.28 (-) 11°C 6°C/ 60 60Min 44.19

14007 Kg 3kg min 52.20% %

From the results in table, it is clear that epimer ratio of A and B is maintained at 0 to -5 °C on lab scale but not on pilot or commercial batch. However as the batch size increases there is substantial variation in epimer ratio at 0 to -5°C. Therefore, this temperature is not suitable for scale up and industrial use. But at temperature -7 to -11 °C the epimer ratio is maintained (within normal standard deviation limits) at pilot as well as commercial batch. In addition, it may be noted that when optimum parameters of temperature and other parameters as set out herein the reaction time is reduced to 60 minutes from 120. Therefore, reducing the cost and increasing the economic viability and industrial applicability.

Example 3: Process for synthesis ofCiclesonide from 16HPN

Preparation of cyclohexane carboxaldehydemetabisulphite complex

200gm of Cyclohexane carboxaldehyde (1.786 mol) was dissolved in 3.0L of denatured sprit (15 volume) and a solution of 190gm of sodium metabisulphite (1.827 mol) in 300ml of purified water (1.5 volume) was added. The resulting precipitate was filtered and washed with 1.0L of denatured sprit(5.0 volume) and dried under vacuum at 50°C, till moisture content less than 6.00%, Yield=400gm (97 %)

Stage I: Preparation of stage-I from 16-HPN

Cyclohexane carboxaldehyde

sodium metabisulphite complex

170gm of 16-HPN (0.4528 mol) was suspended in 3.40L of dichloromethane (20 volume) and treated with 340ml of 70% perchloric acid. (5.65 mol) and 110.5gm of cyclohexane carboxaldehyde metabisulphite complex (0.512 mol) was added in lots while maintaining the temperature between 0°Cto 5°C. The reaction mass was stirred at 0°C to 5°C for 03 hours. In- process check by TLC 16-HPN should be nil and then neutralized with 10% aqueous sodium bicarbonate solution. The organic layer was separated and concentrated under vacuum to obtain a residue which was stripped with methanol (1.0 volume). The solvent was concentrated and the residue was dissolved by refluxing in methanol (5.0 volume). The clear solution was cooled to 0°C to 5.0°C and the resulting solid was filtered and dried at 50°C till moisture content less than 0.50%, Yield=170.0gm (80.0%), HPLC purity=91.68%.

Stage -II Preparation of Ciclesonide from Stage -I

Stage-I Ciclesonide

158gm of stage-I (0.34mol) was suspended in 1.58L of methylene chloride (10.0 volume) at 25°C to 30°C. The reaction mass was chilled to 0°C to 5°C and 81.0ml of triethylamine(0.581 mol) was added, followed by the addition of 79.0ml of isobutyryl chloride [0.75 mol; diluted with 79.0 ml of methylene chloride (0.50 volume)] slowly at 0° to 5°C and maintained at same temperature for 60min. In-process check by TLC, Stage-I should be nil. The reaction mass was diluted with 2.53L of purified water (16.0 volume) , the organic layer was separated and washed with purified water till neutral pH, than organic layer was separated and concentrated under vacuum to obtained a residue. The residue was dissolved by refluxing in 948ml of methanol (6.0 volume); the clear solution was cooled to 0°C to 5°C under stirring and filtered. The product was dried under vacuum at ~50°C till moisture contents comes less than 0.50%, Yield=158.0 gm (87.0%), HPLC purity=95.74%.

(Purification)

120gm of Ciclesonide crude was dissolved by refluxing in 600ml of methanol. The clear solution was chilled to 20°C under stirring and filtered. The product was dried under vacuum at 90°C till moisture content less than 0.50%. Yield=105 gm (87.50%), HPLC purity=99.7 %.

Example 4: Process for synthesis of Desonide from 16HPN acetate

Stage-I : Preparation of Desonide acetate from 16 HPN acetate

Desonide acetate

16HPN acetate 190.0 ml of acetone (7.0 volume) was charged in a glass flask under nitrogen blanketing than added 27 gm of 16HPN acetate (0.0645mol) at ambient temperature. Temperature raised to 28°C (+2°C) and stir for 20 minutes. 1.35 ml of perchloric acid 70% (0.02 lmol) was added at 28°C (+2°C) and stir for 30 minutes. Temperature further raised to 35°C and stir for 60 minutes. In-process check by TLC against 16HPN acetate, it should be nil. Reaction mass cooled to 10°C, filtered and washed with purified water till neutral pH (~7) and finally washed with acetone. Wet material dried at 50°C+5°C till moisture content less than 0.50% to get stage-I. Yield =23gm (77.76%), HPLC Purity=98.28%

Stage-II: Preparation of Desonide from Desonide acetate

Desonide

Desonide acetate

200 ml of methanol (10 volume) and 200ml of methylene dichloride (10 volume) was charged in a glass flask and start argon gas purging. 20 gm of stage- 1 st (0.0436mol) was added at ambient temperature. Cool to 0°C+5°C. 0.40gm of sodium hydroxide (O.Olmol) solution in 20ml of methanol (l.Ovolume) was added at 0°C+5°C. Stir at 0°C+5°C for 120 minutes. In-process check by TLC against stage- 1 st it should be nil. Adjust pH to neutral (~7) by 2.0ml of acetic acid at 0°C+5°C. Distilled the solvent from reaction mass under vacuum while maintaining temperature below 40°C till the volume get reduced to 3 to 4 volume of the input. Cool to 0°C and further added 60ml of purified water and stir for 30 minutes. Filtered, washed with purified water till neutral pH (~7). Wet material dried at 50°C+5°C till moisture content less than 0.50% to get crude Desonide. Yield =14.70gm (80.92%), HPLC Purity=88.15%.

(Purification)

140 ml of methanol (10 volume) and 140 ml of methylene chloride (10 volume) was charged in a glass flask and added 14.0 gm of crude material (0.034mol) than stir till clear solution. Added 1.5 gm of activated charcoal and stir for 30 minutes than filtered through hyflow supercel bed and washed with 30ml of methanol and 30ml of methylene chloride mixture. Combined filtrate and distilled the solvent from reaction mass under vacuum while maintaining temperature below 40°C till the volume reduced to 3 to 4 volume of the input. Cool to 0°C. Filtered the reaction mass and washed with 10ml of precooled methanol. Wet material was dried at 50°C+5°C till moisture content less than 0.50% to get Desonide. Yield=8.60gm, HPLC Purity= 99.43%

lOOgm of 3TR (0.27 mol.)was suspended in 1300ml (13 volume) acetone. Cooled it to -5°C to -10°C than added 4.0 ml (0.062 mol.) perchloric acid solution and 50gm of dibromantin. Maintained the reaction at same temperature for 02 hours. In-process check by TLC against 3TR it should be nil. Added lOOgm of potassium carbonate solution (0.723 mol.) in 5 lots and reaction was maintained at 35°C+2°C. In-process check by TLC against step-I reaction mass, it should be nil. Cooled to 0°C (+5°C) and adjust pH neutral (~7) by 36ml of acetic acid (0.63 mol.). Added 3.0L of purified water (30 volume). Filter and washed with purified water till neutral pH (~7). Wet material was dried at 45°C (+2°C) till moisture content less than 0.50%. Yield =87gm, (83.36%), HPLC Purity=97.883%.

Stage - II:

80gm of stage-I (0.21 mol) was dissolved in 4.0L of acetone (50 volume) and 208ml of purified water (2.6 volume). Cool to -5°C (+2°C) than added 32ml of formic acid (0.85 mol.) and 48gm of potassium permagnate (0.30 mol.) at -5°C (+2°C). Reaction was maintained at - 5°C+2°Cfor one hour. In-process check by TLC against stage-I it should be nil. Added 8gm of sodium metabisulphite (0.042 mol.) In 80 ml purified water (01 volume) solution at -5°C (+2°C). Temperature raised up to 27°C and filtered through hyflow bed and washed with acetone. Acetone was distilled under vacuum till 3 to 4volume of stage-I than cool to 0°C to 5°C and added 480ml of purified water stir and filter and washed with purified water to get wet stage-II. Wet material was dried at 50°C (+5°C) till moisture content less than 3.0%. Yield =78.30gm, (89.88%), HPLC Purity=99.178%. Stage -III:

Stage-ll Stage-

300ml of hydrofluoric acid (12.60mol) was cooled at -25°C to -30°C than added 75gm of stage-II (0.180mol). Reaction was maintained at -25°C to -30°C for 04 hours. In-process check by TLC against stage-II, it should be nil. Reaction mass was cooled to -50°C than added 45ml of acetone (0.60volume) at -45°C to -50°C. Reaction was maintained at -45°C to -50°C for 02 hours. In-process check by TLC against before acetone reaction mass. Added 565ml of purified water at 0°C and 340ml of liq. ammonia at ~20°C than reaction mass was quenched in 410ml of liq. ammonia and 735ml of purified water solution at 15°C (+2°C), stir and filter and washed with purified water till neutral pH. Wet material was dried at 45°C to 50°C, Yield =78.50gm, (91.48%), HPLC Purity=91.593%.

(Purification)

76 gm of stage-Ill Crude (0.16 mol.) was dissolved in 760ml of methylene chloride (lOvolume) and 760ml of methanol (lOvolume) mixture at ambient temperature. Stir till clear solution and added 7.6gm of activated charcoal (0. lOvolume) than stir for 30minutes, filter through hyflow bed and washed with methanol (one volume) and methylene chloride (one volume) mixture. Total filtrate was distilled under vacuum till 3 to 4 volume of input. Cool to 0°C to 5°C and stir for 02 hours. Filtered and washed with minimum precooled methanol, Wet material was dried 45°C to 50°C till moisture contents less than 0.50%, Yield=62gm, HPLC Purity=98.633%.

Stage - IV (Process for synthesis of Triamcinolone acetonide from Stage - III):

Stage- Ill Triamcinolone acetonide

60gm of stage-Ill (0.13 mol) was dissolved in 600ml of methanol (lOvolume) and 600ml of methylene chloride (lOvolume) mixture under argon bubbling. Cool to -5°C+2°C and added 1.2gm of sodium hydroxide (0.03mol.) solution in 60ml of methanol (Olvolume) at -5°C (+2°C). Reaction maintained at -5°C (+2°C) for 03 hours. In-process check by TLC against stage-Ill, it should be nil. Adjust pH neutral (~7) by adding 1.8ml of acetic acid at -5°C (+2°C). Reaction mass was distilled at below 40°C under vacuum till 3 to 4 volume of input. Cool to 30°C and added 120ml of purified water, stir for one hour than filter and washed with purified water till neutral pH (~7). Wet material was dried at 45°C to 50°C till moisture content less than 0.50%, Yield =52gm, (95.04%), HPLC Purity=99.21%

(Purification)

50gm of crude material (0.12 mol.) was dissolved in 1100ml of acetone (22volume) and 100ml of purified water (02volume) at 50°C than added 2.5gm of activated charcoal and stir for one hour at same temperature, Filter through hyflow bed and washed with 120ml of acetone (2.40volume). Filtrate was distilled below 40°C under vacuum till 3 to 4 volume of input. Cool to 0°C to 5°Cand maintained for one hour at same temperature. Filter and washed with water. Wet material was dried at 45°C to 50°C till moisture content less than 0.50%, Yield=43gm, HPLC Purity=99.40%.

Example 6: Process for synthesis of Flunisolide from 16HPN acetate Stage -I (Preparation of Desonide acetate from 16HPN acetate):

1 6 H PN acetate eson e acetate

140ml of acetone (7 volume) was charged in glass flask and start argon blanketing than added 20 gm of 16-HPN acetate (0.048mol) at ambient temperature. Cooled to 28°C (+2°C). 1.0ml of perchloric acid 70% (0.016mol) was added at 28°C (+2°) C and stirred for 30 minutes. Temperature raised up to 35°Cand stirred for 60 minutes. In-process check by TLC against 16-HPN acetate, it should be nil. Reaction mass was cooled to 10°C (+2°C). Reaction mass was filtered and washed with purified water till neutral pH (~7) to get wet material. Wet material was dried at 50°C+5°C till moisture content less than 0.50% to get stage-l st . Yield=17.40gm, (79.40%), HPLC Purity=98.241%.

Stage -II (Preparation of Desonide from Desonide acetate):

170ml of methanol (lOvolume) and 170ml of methylene chloride (lOvolume) was charged in a glass flask and start inert atmosphere. 17gm of stage-l st (0.037mol) was added at ambient temperature. Cooled to -5°C. 0.4gm of sodium hydroxide (O.Olmol) solution in 17ml of methanol was added at 0°C (+5°C). Reaction mass was stirred for 02 hours at 0°C (+5°C). In- process check by TLC against stage- 1 st it should be nil. Neutral pH (~7) was adjusted by acetic acid. Reaction mass was distilled under vacuum at below 40°C till ~ 100ml. Concentrated mass was cooled to 0°C (+5°C) and stir for one hour. Reaction mass was filtered and washed with precooled methanol to get wet material. Wet material was dried at 50°C (+5°C) till moisture content less than 0.50% to get stage-2 nd . Yield=14.0gm, (90.67%), HPLC Purity=99.426%, Single impurity=0.136%.

Stage -III (Preparation of Flunisolide acetate from Desonide):

Desonide Flunisolide acetate

50ml of isopropenyl acetate (5 volume) was charged in a glass flask and added lOgm of stage-2 nd (0.024mol) at ambient temperature than heated to 65°C and added 1.5ml of methane sulphonic acid (0.023mol) and temperature raised up to 80°C and stir for one hour. In-process check by TLC against stage-2, it should be nil. Reaction mass cooled to 25°C and adjust pH neutral (~7) by triethylamine. Reaction mass was distilled under vacuum till last drop and degases with acetonitrile. 90ml of acetonitrile (09 volume) was added and cooled to -5°C and than further added 10ml of purified water. lOgm of selectfluor(0.028mol) was added in two lots at 0°C(+5°C) in 02 volume of acetonitrile. Reaction mass was stirred at 10°C to 15°C for 12 hours. In-process check by TLC against before selectfluor reaction mass it should be nil. Adjust pH neutral (~7) by liq. ammonia solution at 0°C+5°C. Reaction mass was quenched in 500ml of purified water (lOOvolume) at ambient temperature. Reaction mass was filtered and washed with purified water till neutral pH (~7). Wet material was dried at 45°C+5°C till moisture content less than 0.50% to get stage-3 rd . Yield=8.60gm, (75.17%), HPLC Purity= 94.12%.

Stage -IV (Preparation of Flunisolide from Flunisolide acetate):

Flunisolide acetate Flunisolide

80ml of methanol (lOvolume) and 80ml of methylene chloride (lOvolume) was charged in a glass flask under inert atmosphere at ambient temperature than added 8.0gm of stage-3 r (0.017mol) at ambient temperature. Cooled to -5°C and added 0.16gm of sodium hydroxide (0.004mol) solution in 8ml of methanol at -5°C(+5°C) and stir for 02 hours at -5°C(+5°C). In-process check by TLC against stage-3 ' it should be nil. Adjust pH neutral(~7) by acetic acid and reaction mass was distilled under vacuum at below 40°C(+5°C) till ~40ml of volume. Cool to 0°C to 5°C and stir for one hour. Reaction mass was filtered and washed with precooled methanol to get wet material. Wet material was dried at 45°C (+5°C) till moisture content less than 0.50% to get Flunisolide crude. Yield=6.0gm, (82.30%), HPLC Purity=86.50%.

(Purification)

6.0gm of crude Flunisolide(0.014mol) was dissolved in 65ml of ethyl acetate (10.83volume) and 35ml of n-hexane (5.83volume) mixture and clear solution was passed through 60gm of silica gel column. Column was washed with 975ml of ethyl acetate (162.5volume) and 525ml of ft-hexane (87.5volume) mixture. Eluted fraction was distilled under vacuum till 3 to 4 volume of input than cooled it to 0°C and filter to get wet material. Wet material was dried at 50°C (+5°C) till moisture content less than 0.50% to get Flunisolide. Yield=4.28gm, HPLC Purity=95.60%.

Example 7: Process for synthesis of Triamcinolone from 3TR

S

lOOgm of 3TR (0.27mol) was suspended in 1300ml (13 volume) acetone. Cool to -5°C to- 10°C than added 4.0 ml (0.062mol) perchloric acid solution and 50gm of dibromantin. Reaction maintained at same temperature for 02 hours. In-process check by TLC against 3TR, it should be nil. Added lOOgm of potassium carbonate solution (0.723 mol) in 5 lots and reaction was maintained at 35°C (+2°C). In-process check by TLC against step-I reaction mass, it should be nil. Cool to 0°C+5°Cand adjust pH neutral (~7) by 36ml of acetic acid (0.63 mol). Added 3.0L of purified water (30 volume). Filter and washed with purified water till neutral pH (~7). Wet material was dried at 45°C (+2°C) till moisture content less than 0.50% to get stage-I. Yield=85.30gm, (81.74%), HPLC Purity=96.54%. Stage -II:

80gm of stage-I (0.21 mol) was dissolved in 4.0L of acetone (50 volume) and 208ml of purified water (2.6 volume). Cool to -5°C (+2°C) than added 32ml of formic acid (0.85 mol.) and 48gm of potassium per magnate (0.30 mol) at -5°C (+2°C). Reaction was maintained at same temperature for one hour. In-process check by TLC against stage-I, it should be nil. Added sodiummetabisulphite solution (8 gm in 80 ml of water) at -5°C+2°C. Temperature was raised up to 27°C and filtered through hyflow bed and washed with acetone. Acetone was distilled under vacuum till 3 to 4 volume of stage-I than further cooled to 0°C to 5°C and added 480ml of purified water, stirred, filter and washed with purified water to get wet stage- II. Wet material was dried at 50°C (+5°C) till moisture content less than 3.0% to get stage-II. Yield=82gm, (94.13%), HPLC Purity=97.75%.

Stage -III:

Stage-II Triamcinolone acetate

160ml of hydrofluoric acid (70%) (6.72mol) was cooled at -25°C to -30°C than added 40gm of stage-II (0.096mol). Reaction was maintained at -25°C to -30°C for 04 hours. In-process check by TLC against stage-II, it should be nil. Added 280ml of purified water at 0°C and 650ml of liq. ammonia at 20°C than reaction mass was quenched in 200ml of liq. ammonia and 500ml of purified water solution at 15°C(+2°C), stirred, filtered and washed with purified water till neutral pH(~7). Wet material was dried at 45°C to 50°C to get stage-Ill Yield=40gm, (95.42%), HPLC Purity=88.71%

(Purification)

40gm of stage-Ill crude (0.0916 mol) was refluxed in 160ml of acetone. Cool to 0°C. Filtered and washed with minimum precooled acetone. Wet material was dried at 50°C+5°C till moisture content comes less than 0.50% to get stage-Ill. Yield=24.9gm HPLC Purity=95.17%.

24gm of stage-Ill (0.055mol) was dissolved in 240ml of methanol (lOvolume) and 240ml of methylene chloride (lOvolume) mixture under argon bubbling. Cool to -5°C+2°C and added 0.48gm of sodium hydroxide (0.012mol) solution in 24ml of methanol (Olvolume) at - 5°C+2°C. Reaction was maintaining at -5°C (+2°C) for 03hours. In-process check by TLC against stage-Ill, it should be nil. Adjust pH neutral by adding 0.70ml of acetic acid at -5°C (+2°C). Reaction mass distilled at below 40°C under vacuum till 04-05 volume of input. Cooled to 0°C+5°Cand stir for one hour than filtered and washed with minimum precooled methanol. Wet material was dried at 45°C to 50°C till moisture content less than 0.50%. Yield=18.50gm, (85.29%), HPLC Purity=98.60%.

Example 8: Process for synthesis of Triamcinolone Hexacetonide from 3TR

S

lOOgm of 3TR (0.27288 mol) was suspended in 1300ml (13 volume) acetone. Cool to -5°C to -10°C than added 4.0 ml (0.0625 mol) perchloric acid solution and 50gm of dibromantin. Reaction was maintained at same temperature for 02 hours. In-process check by TLC against 3TR, it should be nil. Added lOOgm of potassium carbonate solution (0.723 mol) in 5 lots and reaction was maintained at 35°C (+2°C). In-process check by TLC against step-I reaction mass, it should be nil. Cool to 0°C (+5°C) and adjust pH neutral (~7) by 36ml of acetic acid (0.63 mol). Added 3.0L of purified water (30 volume). Filter and washed with purified water till neutral pH. Wet material was dried at45°C(+2°C) till moisture content less than 0.50% to get stage-l st . Yield =87gm, (83.36%), HPLC Purity=97.883%. Stage-II :

80gm of stage-I (0.21 mol) was dissolved in 4.0L of acetone (50 volume) and 208ml of purified water (2.6 volume). Cool to -5°C than added 32ml of formic acid (0.85 mol.) and 48gm of potassium permanganate (0.30 mol) at -5°C+2°C. Reaction maintained at -5°C (+2°C) for one hour. In-process check by TLC against stage-I, it should be nil. Added sodium metabisulphite solution (8 gm in 80 ml water) at -5°C (+2°C). Temperature raised up to 27°Cand filtered through hyflow bed and washed with acetone. Acetone was distilled under vacuum till 3 to 4 volume of stage-I than cooled to 0°C to 5°C and added 480ml of purified water, stirred, filtered and washed with purified water to get wet stage-II. Wet material was dried at 50°C (+5°C) till moisture content less than 3.0% to get stage-2 nd . Yield=78.30gm, (89.88%), HPLC Purity=99.18%.

Stage - III:

300ml of hydrofluoric acid (12.60mol) was cooled at -25°C to -30°C than added 75gm of stage-II (0.180mol). Reaction was maintained at -25°C to -30°C for 04 hours. In-process check by TLC against stage-II. It should be nil. Reaction mass was cooled to -50°C than added 45ml of acetone (0.60volume) at -45°C to -50°C. Reaction maintained at -45°Cto - 50°C for 02 hours. In-process check by TLC against reaction input, it should be nil. Added 565ml of purified water at 0°C and 340ml of liq. ammonia at 20°C than reaction mass was quenched in 410ml of liq. ammonia and 735ml of purified water solution at 15°C(+2°C), stirred, filtered and washed with purified water till neutral pH (~7). Wet material was dried at 45°C to 50°Cto get stage-3 rd . Yield=78.50gm, (91.48%), HPLC Purity=91.59%.

(Purification)

76 gm of stage-Ill Crude (0.16 mol) was dissolved in 760ml of methylene chloride (01 volume) and 760ml of methanol (lOvolume) mixture at ambient temperature. Stirred till clear solution and added 7.6gm of activated charcoal (0. lOvolume) than further stir for 30 minutes and filtered through hyflow bed and washed with methanol (one volume) and methylene chloride (one volume) mixture. Total filtrate was distilled under vacuum till 3 to 4 volume of input. Cooled to 0°C to 5°Cand stir for 02 hours. Filtered and washed with minimum precooled methanol. Wet material was dried at 45°C to 50°C till moisture content less than 0.50% to get purified stage-3 rd . Yield=62gm, HPLC Purity=98.633%

Stage -IV : (Preparation of Triamcinolone acetonide from Stage - III)

Stage- Ill Triamcinolone acetonide

60gm of stage-Ill (0.1259 mol) dissolved in 600ml of methanol (lOvolume) and 600ml of methylene chloride (lOvolume) mixture under inert atmosphere. Cool to -5°C and added 1.2gm of sodium hydroxide (0.03mol) solution in 60ml of methanol (Olvolume) at -5°C (+2°C). Reaction maintained at -5°C+2°C for 03 hours. In-process check by TLC against stage-Ill, it should be nil. Adjust pH neutral (~7) by adding 1.8ml of acetic acid at -5°C+2°C. Reaction mass was distilled below 40°C under vacuum till 3 to 4 volume of input. Cool to

30°C and added 120ml of purified water, stir for one hour than filtered and washed with purified water till neutral pH (~7). Wet material was dried at 45°C to 50°C till moisture content less than 0.50% to get stage-4 111 (Triamcinolone acetonide). Yield=52gm, (95.04%), HPLC Purity=99.21%.

(Purification)

50gm of crude material (0.12 mol) dissolved in 1100ml of acetone (22volume) and 100ml of purified water (02volume) at 50°C than added 2.5gm of activated charcoal and stirred for one hour at same temperature. Filter through hyflow bed and washed with 120ml acetone (2.40volume). Filtrate was distilled below 40°C under vacuum till 3 to 4 volume of input. Cool to 0°C to 5°C and maintained for one hour at same temperature. Filtered and washed with water. Wet material was dried at 45°C to 50°C till moisture content less than 0.50% to get purified stage-4 th . Yield =43gm, HPLC Purity=99.40%

-V: (Preparation of Triamcinolone Hexacetonide from Triamcinolone acetonide):

50ml of pyridine (lOvolume) charged in a glass flask and added lOgm of Triamcinolone acetonide (0.023mol) at ambient temperature. Heated to 80°C to 90°C than added 10ml of 3, 3-dimethyl butyryl chloride (O.l lmol) at 80°C to 90°C. Stirred at 80°C to 90°C for 02 hours. In-process check by TLC against Triamcinolone acetonide, it should be nil. Reaction mass cooled to ambient temperature and reaction mass was quenched in 1000ml of purified water (lOOvolume) at ambient temperature, stir for one hour than filtered and washed with purified water till neutral pH (~7). Wet material was dried at 50°C (+5°C) till moisture content less than 1.0% to get stage-5 th (Triamcinolone Hexacetonide). Yield=12gm, (97.90%), HPLC Purity=98.63%.

(Purification)

120ml of methanol and 120ml of methylene chloride charged in a glass flask and added 12gm of crude material, stir till clear solution than added 1.2gm of activated charcoal and stir for 30 minutes. Filtered through hyflow bed and washed with 12ml of methanol and 12ml of methylene chloride mixture. Total filtrate was distilled under vacuum at below 40°C till 5 to 6 volume of crude. Cooled to 0°C+5°C and stir for one hour. Filtered and washed with 12ml of precooled methanol. Wet material was dried at 40°C+5°C till moisture content less than 0.50% to get TrimcinolneHexacetonide. Yield=8.8gm, HPLC Purity=99.625%